Skip to navigation Skip to content

Idiopathic pulmonary fibrosis (IPF) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051122

Expand/Collapse all sectionsExpand all


This document outlines details of PBS subsidised nintedanib and pirfenidone for patients with idiopathic pulmonary fibrosis (IPF).

IPF and listing dates

IPF is a chronic condition affecting the lungs.

Listing dates are:

  • nintedanib - 1 May 2017
  • pirfenidone - 1 July 2017

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex Drugs Programs team and choose the option relevant to the condition treated.

The Resources page contains links to application forms, contact details, item and restriction codes, the PBS schedule and the Services Australia website.

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Processing and National Demand Allocation (PaNDA)

Process telephone Authority approval application

Processing Complex Authority Required Listings

Written Authority Required Drugs